Compare Eli Lilly And Co (LLY) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nasdaq Inc — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while Nasdaq Inc trades at $93.65 (market cap $51.63B). The key difference: Eli Lilly And Co is far larger — about 20.1× Nasdaq Inc's market cap, and Nasdaq Inc pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Nasdaq Inc for 126 Days on average.
| LLY | NDAQ | |
|---|---|---|
Market Cap | $1.04T | $51.63B |
Volume | 3,064,878 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $1.28K | $100.98 |
52-Week Low | $799.57 | $76.85 |
Typical Hold Time | 93 Days | 126 Days |
Enterprise Value | $1.09T | $58.09B |
Dividend Yield | 0.59% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Nasdaq Inc. (NDAQ) trades at $93.65, up 1.87% on the day, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting further upside, while recent earnings beats and a 22.52% net income margin highlight robust profitability. Positive news includes the addition of Moderna to the Nasdaq-100 Index and HSBC adopting Nasdaq's Calypso platform, signaling business growth.
Outlook remains favorable with a consensus price target of $110.43, implying 18% upside. Key risks include cash flow volatility and high debt levels, but analyst sentiment is strongly bullish with 61% buy ratings. Revenue growth and AI-driven platform adoption present opportunities, though market volatility and competitive pressures warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
